Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents
Top Cited Papers
- 1 May 2006
- journal article
- research article
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 1 (3) , 128-137
- https://doi.org/10.1002/cmmi.100
Abstract
This paper compares the physicochemical properties of six low molecular weight clinical complexes of gadolinium studied under identical experimental conditions. Magnevist®, Dotarem®, Omniscan®, ProHance®, MultiHance® and Gadovist® were investigated by oxygen‐17 relaxometry at different temperatures and by proton relaxometry at various magnetic fields, temperatures and media [pure water, zinc(II)‐containing aqueous solutions and HSA‐containing solutions]. Osmolality, viscosity and stability versus transmetallation by zinc(II) ions were added for a more comprehensive description. The relaxivities of the clinical formulations as measured in water are similar in the imaging magnetic field region, with a slightly better performance for MultiHance. This can be explained by a shorter distance between the hydrogen nuclei of the water molecule bound to the Gd3+ ion and this paramagnetic centre. In contrast to the open‐chain complexes, all macrocyclic systems (Dotarem, ProHance and Gadovist) are insensitive to transmetallation by zinc ions. The stability of the open‐chain complexes with respect to transmetallation depends on the chemical structure of the ligand, with a better stability for MultiHance. The presence of human serum albumin has no significant effect on the proton relaxivity of Magnevist, Dotarem, Omniscan, ProHance and Gadovist but markedly increases the relaxivity of MultiHance because of a non‐covalent interaction with the protein. As a result, the relaxivity of MultiHance in HSA‐containing media of fixed concentration decreases with increasing concentration of the contrast agent. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 32 references indexed in Scilit:
- Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrolEuropean Radiology, 2002
- Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and ApplicationsChemical Reviews, 1999
- Synthesis and Structure of a New Macrocyclic Polyhydroxylated Gadolinium Chelate Used as a Contrast Agent for Magnetic Resonance ImagingInorganic Chemistry, 1997
- Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imagingEuropean Journal of Radiology, 1995
- Novel Contrast Agents for Magnetic Resonance Imaging. Synthesis and Characterization of the Ligand BOPTA and Its Ln(III) Complexes (Ln = Gd, La, Lu). X-ray Structure of Disodium (TPS-9-145337286-C-S)-[4-Carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa- 5,8,11-triazatridecan-13-oato(5-)]gadolinate(2-) in a Mixture with Its EnantiomerInorganic Chemistry, 1995
- The relationship between thermodynamics and the toxicity of gadolinium complexesMagnetic Resonance Imaging, 1990
- Gd-DOTA: characterization of a new paramagnetic complex.Radiology, 1988
- Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and designChemical Reviews, 1987
- Gd(DOTA): An alternative to Gd(DTPA) as a T1,2 relaxation agent for NMR imaging or spectroscopyMagnetic Resonance in Medicine, 1986
- Characteristics of gadolinium-DTPA complex: a potential NMR contrast agentAmerican Journal of Roentgenology, 1984